Nanoviricides Inc (NNVC)

$1.77 +0.12 (7.27%)
Market Cap 37.92M
Revenue (ttm) 0.00
Net Income (ttm) -9.47M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 680,100
Avg Vol 1,100,776
Day's Range N/A - N/A
Shares Out 22.98M
Stochastic %K 89%
Beta 1.67
Analysts Strong Sell
Price Target $6.33

Company Profile

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gumm...

Industry: Biotechnology
Sector: Healthcare
Phone: 203 937 6137
Address:
1 Controls Drive, Shelton, United States
BmoreBoy89
BmoreBoy89 Jul. 15 at 12:37 PM
$SNGX $NNVC SNGX is next!
0 · Reply
Love1010
Love1010 Jul. 14 at 10:30 PM
$NNVC there is wisdom on these boards
0 · Reply
SharpMoney420
SharpMoney420 Jul. 14 at 9:25 PM
$NNVC I wouldn't wipe my ass with this stock
0 · Reply
Usmc2434
Usmc2434 Jul. 14 at 7:35 PM
$NNVC be here tomorrow for the run up 🤙🏾
0 · Reply
STRAYNUT
STRAYNUT Jul. 14 at 5:51 PM
$NNVC Short Interest (06/30/26) Shares Sold Short 886,106 Change from Last 17.49% Percent of Float 3.97% wsj.com/market-data/quotes/... Imagine what would happen when the shorts start covering!!
0 · Reply
Channelchek
Channelchek Jul. 14 at 5:23 PM
Noble Capital Markets Research Report: NanoViricides ($NNVC) – NanoViricides Announces Phase 2 Ebola Trial Approval and Prepares Next Regulatory Filing Phase 2 Ebola Trial Advancing As Expected. Nanoviricides announced that it has received approval from the National Ethics Committee in the Democratic Republic of Congo (DRC) for its Phase 2 clinical trial of NV-387 in Ebola. The next step is the filing of a Clinical Trial Application with ACOREP, the DRC regulatory authority. Read full report here: https://www.channelchek.com/news-channel/nanoviricides-nnvc-nanoviricides-announces-phase-2-ebola-trial-approval-and-prepares-next-regulatory-filing
0 · Reply
STRAYNUT
STRAYNUT Jul. 14 at 5:15 PM
$NNVC NNVC: Nuggets from yesterday's PR: (All are quotes from the document). 1. NV-387 Oral Gummies has been approved by ACOREP for a Phase II clinical trial as a Treatment for Mpox in DRC. 2. NV-387 is the ONLY oral drug under consideration as a treatment of Ebola, in contrast to all others which must be administered by INFUSION. 3. Infusions are difficult to implement and also are not scalable in a large outbreak scenario, which is expected with Ebola. 4. Currently there is NO treatment or vaccine for the Bundibugyo virus. https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/as-ebola-spreads-in-two-more-provinces-nanoviricides-has-received-nat-1190201
0 · Reply
drkazmd65
drkazmd65 Jul. 14 at 4:01 PM
$NNVC - If Diwan can pull off a Phase 2 trial on an absolute shoestring budget AND the gummies help save Ebola patients,... Then I don't think near-term funding is going to be an issue for this company. Some government, NGO or pharma partner is very likely to appear out of the background with very deep pockets. But he's got to get the trial(s) going and there have to be solid results.
1 · Reply
STRAYNUT
STRAYNUT Jul. 14 at 12:47 AM
$NNVC
0 · Reply
BigBadBeethoven
BigBadBeethoven Jul. 13 at 9:23 PM
$NNVC "GUMMIES FOR EBOLA" Has a nice ring to it.... kind of like CASH FOR KIDS
0 · Reply
Latest News on NNVC
NanoViricides gets National Ethics Committee approval for Phase II NV-387 trial

2026-07-13T13:30:07.000Z - 2 days ago

NanoViricides gets National Ethics Committee approval for Phase II NV-387 trial

As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo

Jul 13, 2026, 9:27 AM EDT - 2 days ago

As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo

Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily

Jul 8, 2026, 8:30 AM EDT - 7 days ago

Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily

NanoViricides initiated with an Outperform at Noble Capital

2026-07-06T13:30:07.000Z - 9 days ago

NanoViricides initiated with an Outperform at Noble Capital

NanoViricides advances towards Phase II clinical trial of NV-387

2026-07-06T12:45:15.000Z - 9 days ago

NanoViricides advances towards Phase II clinical trial of NV-387

As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo

Jul 6, 2026, 8:30 AM EDT - 9 days ago

As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo

NanoViricides granted Rare Pediatric Disease Drug designation for NV-387

2026-06-29T12:41:04.000Z - 16 days ago

NanoViricides granted Rare Pediatric Disease Drug designation for NV-387

US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher

Jun 29, 2026, 8:30 AM EDT - 16 days ago

US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher

NanoViricides ships NV-387 oral gummies for Phase II trials to DR Congo

2026-06-22T13:35:44.000Z - 23 days ago

NanoViricides ships NV-387 oral gummies for Phase II trials to DR Congo

NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo

Jun 22, 2026, 9:30 AM EDT - 23 days ago

NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo

NanoViricides files to sell 1.33M shares of common stock for holders

2026-06-15T20:41:08.000Z - 4 weeks ago

NanoViricides files to sell 1.33M shares of common stock for holders

NanoViricides announces proposal approved by Pillar Committee in DRC

2026-06-15T12:41:50.000Z - 4 weeks ago

NanoViricides announces proposal approved by Pillar Committee in DRC

As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR Congo

Jun 15, 2026, 8:30 AM EDT - 4 weeks ago

As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR Congo

NanoViricides proposes Phase II trial of NV-387 gummies in Ebola

2026-06-08T12:48:36.000Z - 5 weeks ago

NanoViricides proposes Phase II trial of NV-387 gummies in Ebola

As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies

Jun 8, 2026, 8:30 AM EDT - 5 weeks ago

As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies

NanoViricides files $50M mixed securities shelf

2026-06-05T20:35:24.000Z - 5 weeks ago

NanoViricides files $50M mixed securities shelf

In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides

May 26, 2026, 8:30 AM EDT - 7 weeks ago

In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides

NanoViricides Announces Closing of ~$2 Million Registered Direct Offering

May 18, 2026, 11:55 PM EDT - 2 months ago

NanoViricides Announces Closing of ~$2 Million Registered Direct Offering

NanoViricides emphasizes need for Ebolavirus antiviral drug

2026-05-18T12:35:07.000Z - 2 months ago

NanoViricides emphasizes need for Ebolavirus antiviral drug

Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides

May 18, 2026, 8:30 AM EDT - 2 months ago

Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides

NanoViricides prices $2M registered direct offering

2026-05-15T15:36:54.000Z - 2 months ago

NanoViricides prices $2M registered direct offering

NanoViricides reports Q1 EPS (9c) vs. (14c) last year

2026-05-15T13:02:44.000Z - 2 months ago

NanoViricides reports Q1 EPS (9c) vs. (14c) last year

NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering

May 15, 2026, 8:35 AM EDT - 2 months ago

NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering

NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II

May 15, 2026, 8:00 AM EDT - 2 months ago

NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II

NanoViricides says hantavirus incident highlights need for antiviral drugs

2026-05-11T15:05:03.000Z - 2 months ago

NanoViricides says hantavirus incident highlights need for antiviral drugs

Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides

May 11, 2026, 8:30 AM EDT - 2 months ago

Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides

NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference

May 6, 2026, 3:37 PM EDT - 2 months ago

NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference

NanoViricides announces NV-387 granted ODD by U.S. FDA OOPD

2026-05-04T13:06:44.000Z - 2 months ago

NanoViricides announces NV-387 granted ODD by U.S. FDA OOPD

NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA

May 4, 2026, 8:30 AM EDT - 2 months ago

NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA

NanoViricides measles virus treatment granted FDA orphan status

2026-04-28T16:50:20.000Z - 2 months ago

NanoViricides measles virus treatment granted FDA orphan status

NanoViricides says NV-387 can help control spread of measles

2026-04-21T12:55:54.000Z - 3 months ago

NanoViricides says NV-387 can help control spread of measles

Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides

Apr 21, 2026, 8:30 AM EDT - 3 months ago

Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides

NanoViricides files application for RPDD for NV-387 with U.S. OPDD

2026-04-07T14:27:12.000Z - 3 months ago

NanoViricides files application for RPDD for NV-387 with U.S. OPDD

Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides

Apr 7, 2026, 8:30 AM EDT - 3 months ago

Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides

NanoViricides plans to commence Phase II trial of NV-387 for Monkeypox

2026-04-01T12:48:44.000Z - 3 months ago

NanoViricides plans to commence Phase II trial of NV-387 for Monkeypox

Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides

Apr 1, 2026, 8:30 AM EDT - 3 months ago

Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides

NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete

Mar 11, 2026, 8:30 AM EDT - 4 months ago

NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete

MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides

Feb 12, 2026, 8:30 AM EST - 5 months ago

MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides

Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides

Feb 10, 2026, 8:30 AM EST - 5 months ago

Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides

NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres

Feb 2, 2026, 8:30 AM EST - 5 months ago

NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres

NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave - NV-387 is Effective Against H3N2

Jan 13, 2026, 8:30 AM EST - 6 months ago

NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave - NV-387 is Effective Against H3N2

NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles

Dec 1, 2025, 8:30 AM EST - 8 months ago

NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles

NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position

Nov 17, 2025, 8:30 AM EST - 8 months ago

NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position

NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2

Nov 14, 2025, 8:30 AM EST - 8 months ago

NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2

NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

Nov 12, 2025, 5:01 PM EST - 8 months ago

NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

Nov 11, 2025, 8:30 AM EST - 8 months ago

NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo

Nov 10, 2025, 8:30 AM EST - 8 months ago

NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo

NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT

Nov 5, 2025, 8:30 AM EST - 9 months ago

NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT

NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd

Nov 3, 2025, 8:30 AM EST - 9 months ago

NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd

Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive

Oct 29, 2025, 8:45 AM EDT - 9 months ago

Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive

NanoViricides to Present at the PODD 2025 Conference in Boston on October 27

Oct 27, 2025, 8:45 AM EDT - 9 months ago

NanoViricides to Present at the PODD 2025 Conference in Boston on October 27

In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides

Oct 22, 2025, 8:45 AM EDT - 9 months ago

In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides

A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus

Oct 20, 2025, 8:45 AM EDT - 9 months ago

A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus

NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses

Oct 15, 2025, 8:45 AM EDT - 9 months ago

NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses

NanoViricides, Inc. Has Filed its Annual Report

Sep 30, 2025, 8:45 AM EDT - 10 months ago

NanoViricides, Inc. Has Filed its Annual Report

RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025

Sep 11, 2025, 8:30 AM EDT - 10 months ago

RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025

NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025

Sep 9, 2025, 8:30 AM EDT - 11 months ago

NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025

A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials

Aug 18, 2025, 8:30 AM EDT - 11 months ago

A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials

Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides

Jul 30, 2025, 8:30 AM EDT - 1 year ago

Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides

NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value

Jul 23, 2025, 8:30 AM EDT - 1 year ago

NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value

Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides

Jul 21, 2025, 6:30 AM EDT - 1 year ago

Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides

WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides

Jul 16, 2025, 8:30 AM EDT - 1 year ago

WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides

With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan

Jun 18, 2025, 6:30 AM EDT - 1 year ago

With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan

NanoViricides Measles Drug Development Animal Study is Imminent

Jun 4, 2025, 6:55 AM EDT - 1 year ago

NanoViricides Measles Drug Development Animal Study is Imminent

NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025

May 28, 2025, 6:30 AM EDT - 1 year ago

NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025

The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan

May 22, 2025, 6:30 AM EDT - 1 year ago

The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan

Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution

May 14, 2025, 6:30 AM EDT - 1 year ago

Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution

NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC

May 5, 2025, 6:30 AM EDT - 1 year ago

NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC

BmoreBoy89
BmoreBoy89 Jul. 15 at 12:37 PM
$SNGX $NNVC SNGX is next!
0 · Reply
Love1010
Love1010 Jul. 14 at 10:30 PM
$NNVC there is wisdom on these boards
0 · Reply
SharpMoney420
SharpMoney420 Jul. 14 at 9:25 PM
$NNVC I wouldn't wipe my ass with this stock
0 · Reply
Usmc2434
Usmc2434 Jul. 14 at 7:35 PM
$NNVC be here tomorrow for the run up 🤙🏾
0 · Reply
STRAYNUT
STRAYNUT Jul. 14 at 5:51 PM
$NNVC Short Interest (06/30/26) Shares Sold Short 886,106 Change from Last 17.49% Percent of Float 3.97% wsj.com/market-data/quotes/... Imagine what would happen when the shorts start covering!!
0 · Reply
Channelchek
Channelchek Jul. 14 at 5:23 PM
Noble Capital Markets Research Report: NanoViricides ($NNVC) – NanoViricides Announces Phase 2 Ebola Trial Approval and Prepares Next Regulatory Filing Phase 2 Ebola Trial Advancing As Expected. Nanoviricides announced that it has received approval from the National Ethics Committee in the Democratic Republic of Congo (DRC) for its Phase 2 clinical trial of NV-387 in Ebola. The next step is the filing of a Clinical Trial Application with ACOREP, the DRC regulatory authority. Read full report here: https://www.channelchek.com/news-channel/nanoviricides-nnvc-nanoviricides-announces-phase-2-ebola-trial-approval-and-prepares-next-regulatory-filing
0 · Reply
STRAYNUT
STRAYNUT Jul. 14 at 5:15 PM
$NNVC NNVC: Nuggets from yesterday's PR: (All are quotes from the document). 1. NV-387 Oral Gummies has been approved by ACOREP for a Phase II clinical trial as a Treatment for Mpox in DRC. 2. NV-387 is the ONLY oral drug under consideration as a treatment of Ebola, in contrast to all others which must be administered by INFUSION. 3. Infusions are difficult to implement and also are not scalable in a large outbreak scenario, which is expected with Ebola. 4. Currently there is NO treatment or vaccine for the Bundibugyo virus. https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/as-ebola-spreads-in-two-more-provinces-nanoviricides-has-received-nat-1190201
0 · Reply
drkazmd65
drkazmd65 Jul. 14 at 4:01 PM
$NNVC - If Diwan can pull off a Phase 2 trial on an absolute shoestring budget AND the gummies help save Ebola patients,... Then I don't think near-term funding is going to be an issue for this company. Some government, NGO or pharma partner is very likely to appear out of the background with very deep pockets. But he's got to get the trial(s) going and there have to be solid results.
1 · Reply
STRAYNUT
STRAYNUT Jul. 14 at 12:47 AM
$NNVC
0 · Reply
BigBadBeethoven
BigBadBeethoven Jul. 13 at 9:23 PM
$NNVC "GUMMIES FOR EBOLA" Has a nice ring to it.... kind of like CASH FOR KIDS
0 · Reply
BigBadBeethoven
BigBadBeethoven Jul. 13 at 7:26 PM
$NNVC it looks like NNVC only has about 6 months cash . That's probably what's holding it back. I noticed quite a few services have been pumping this stock.... and maybe it should be pumped.....but only 1/2 year of cash means they're going to need to do an offering or come up with something else pretty quickly. Nice platform though could be a winner
1 · Reply
LewisDaKat
LewisDaKat Jul. 13 at 3:00 PM
$NNVC As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo https://marketwirenews.com/stock/nnvc/news/as-ebola-spreads-in-two-more-provinces-nanoviricides-6747271766183780.html?utm_source=stocktwits
0 · Reply
Staschu
Staschu Jul. 13 at 2:42 PM
$NNVC Hope they can get the clinical trials started soon.🤗
0 · Reply
focafoca99
focafoca99 Jul. 13 at 2:16 PM
$NNVC got ethics approval for a Phase II Ebola trial of its NV-387 oral gummies.
0 · Reply
drkazmd65
drkazmd65 Jul. 13 at 1:43 PM
$NNVC - New PR from the corporate website: 13-July-2026 - As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo. Shelton, Connecticut - July 13, 2026. NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that it has received National Ethics Committee approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus in the Democratic Republic of Congo (DRC). The Company is now getting ready to file a Clinical Trial Application to ACOREP, the regulatory agency in DRC. NanoViricides has already put together a team with a renowned Principal Investigator and with support from a well known University in the Ebola-affected region for the execution of this clinical trial after regulatory approvals.,...
0 · Reply
STRAYNUT
STRAYNUT Jul. 11 at 7:27 PM
$NNVC
0 · Reply
STRAYNUT
STRAYNUT Jul. 11 at 12:09 AM
$NNVC Short Interest (06/30/26) Shares Sold Short 886,106 Change from Last 17.49% Percent of Float 3.97% https://www.wsj.com/market-data/quotes/NNVC
0 · Reply
STRAYNUT
STRAYNUT Jul. 9 at 10:28 AM
$NNVC Of interest, the Oral Gummies are manufactured in blister packs of six outside the clean rooms at the company lab in Shelton, CT using GMP standards only. Dosing for any viral-infected patient is one Gummy each morning placed carefully on the tongue for 12 consecutive days, which should be enough to be highly effective against any Ebola virus strain as well as Mpox.
2 · Reply
Love1010
Love1010 Jul. 7 at 3:49 PM
$NNVC this has always been ... Pumps become dumps quickly
1 · Reply
CoffeeRocks
CoffeeRocks Jul. 7 at 3:35 AM
$NNVC $AEMD $CODX $VRAX Bio week Oil 💩 Crypto 💩 Bio 🥳
0 · Reply
mikesterz7
mikesterz7 Jul. 6 at 7:55 PM
$NNVC The biotech firm said it is progressing towards a Phase II clinical trial of its antiviral drug NV-387 for the Bundibugyo Ebola outbreak in the Democratic Republic of Congo.
0 · Reply
LewisDaKat
LewisDaKat Jul. 6 at 7:30 PM
$NNVC InvestorNewsBreaks - NanoViricides (NYSE American: NNVC) Advances NV-387 Toward Phase II Trial for Bundibugyo Ebola in DRC https://marketwirenews.com/stock/nnvc/news/investornewsbreaks-nanoviricides-nyse-american-nnvc--6471355481144888.html?utm_source=stocktwits
0 · Reply